The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Human Coagulation Factor VIII-Global Market Insights and Sales Trends 2025
Synopsis
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
The global Human Coagulation Factor VIII market size is expected to reach US$ 15770 million by 2029, growing at a CAGR of 6.3% from 2023 to 2029. The market is mainly driven by the significant applications of Human Coagulation Factor VIII in various end use industries. The expanding demands from the Hemophilia A, Spontanous / Trauma, Surgical and Other, are propelling Human Coagulation Factor VIII market. Recombinant Factor VIII, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Plasma-derived Factor VIII segment is estimated at % CAGR for the next seven-year period.
Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Coagulation Factor VIII, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Coagulation Factor VIII market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Coagulation Factor VIII market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Coagulation Factor VIII sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Coagulation Factor VIII covered in this report include Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk and Greencross, etc.
The global Human Coagulation Factor VIII market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Global Human Coagulation Factor VIII market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Coagulation Factor VIII market, Segment by Type:
Recombinant Factor VIII
Plasma-derived Factor VIII
Global Human Coagulation Factor VIII market, by Application
Hemophilia A
Spontanous / Trauma
Surgical
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Coagulation Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
The global Human Coagulation Factor VIII market size is expected to reach US$ 15770 million by 2029, growing at a CAGR of 6.3% from 2023 to 2029. The market is mainly driven by the significant applications of Human Coagulation Factor VIII in various end use industries. The expanding demands from the Hemophilia A, Spontanous / Trauma, Surgical and Other, are propelling Human Coagulation Factor VIII market. Recombinant Factor VIII, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Plasma-derived Factor VIII segment is estimated at % CAGR for the next seven-year period.
Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Coagulation Factor VIII, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Coagulation Factor VIII market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Coagulation Factor VIII market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Coagulation Factor VIII sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Coagulation Factor VIII covered in this report include Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk and Greencross, etc.
The global Human Coagulation Factor VIII market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Global Human Coagulation Factor VIII market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Coagulation Factor VIII market, Segment by Type:
Recombinant Factor VIII
Plasma-derived Factor VIII
Global Human Coagulation Factor VIII market, by Application
Hemophilia A
Spontanous / Trauma
Surgical
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Coagulation Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Human Coagulation Factor VIII Market Overview
1.1 Human Coagulation Factor VIII Product Overview
1.2 Human Coagulation Factor VIII Market Segment by Type
1.2.1 Recombinant Factor VIII
1.2.2 Plasma-derived Factor VIII
1.3 Global Human Coagulation Factor VIII Market Size by Type
1.3.1 Global Human Coagulation Factor VIII Market Size Overview by Type (2018-2029)
1.3.2 Global Human Coagulation Factor VIII Historic Market Size Review by Type (2018-2023)
1.3.3 Global Human Coagulation Factor VIII Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Human Coagulation Factor VIII Sales Breakdown by Type (2018-2023)
1.4.2 Europe Human Coagulation Factor VIII Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Human Coagulation Factor VIII Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Human Coagulation Factor VIII Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Human Coagulation Factor VIII Sales Breakdown by Type (2018-2023)
2 Global Human Coagulation Factor VIII Market Competition by Company
2.1 Global Top Players by Human Coagulation Factor VIII Sales (2018-2023)
2.2 Global Top Players by Human Coagulation Factor VIII Revenue (2018-2023)
2.3 Global Top Players by Human Coagulation Factor VIII Price (2018-2023)
2.4 Global Top Manufacturers Human Coagulation Factor VIII Manufacturing Base Distribution, Sales Area, Product Type
2.5 Human Coagulation Factor VIII Market Competitive Situation and Trends
2.5.1 Human Coagulation Factor VIII Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Human Coagulation Factor VIII Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Coagulation Factor VIII as of 2022)
2.7 Date of Key Manufacturers Enter into Human Coagulation Factor VIII Market
2.8 Key Manufacturers Human Coagulation Factor VIII Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Human Coagulation Factor VIII Status and Outlook by Region
3.1 Global Human Coagulation Factor VIII Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Human Coagulation Factor VIII Historic Market Size by Region
3.2.1 Global Human Coagulation Factor VIII Sales in Volume by Region (2018-2023)
3.2.2 Global Human Coagulation Factor VIII Sales in Value by Region (2018-2023)
3.2.3 Global Human Coagulation Factor VIII Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Human Coagulation Factor VIII Forecasted Market Size by Region
3.3.1 Global Human Coagulation Factor VIII Sales in Volume by Region (2024-2029)
3.3.2 Global Human Coagulation Factor VIII Sales in Value by Region (2024-2029)
3.3.3 Global Human Coagulation Factor VIII Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Human Coagulation Factor VIII by Application
4.1 Human Coagulation Factor VIII Market Segment by Application
4.1.1 Hemophilia A
4.1.2 Spontanous / Trauma
4.1.3 Surgical
4.1.4 Other
4.2 Global Human Coagulation Factor VIII Market Size by Application
4.2.1 Global Human Coagulation Factor VIII Market Size Overview by Application (2018-2029)
4.2.2 Global Human Coagulation Factor VIII Historic Market Size Review by Application (2018-2023)
4.2.3 Global Human Coagulation Factor VIII Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Human Coagulation Factor VIII Sales Breakdown by Application (2018-2023)
4.3.2 Europe Human Coagulation Factor VIII Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Human Coagulation Factor VIII Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Human Coagulation Factor VIII Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Human Coagulation Factor VIII Sales Breakdown by Application (2018-2023)
5 North America Human Coagulation Factor VIII by Country
5.1 North America Human Coagulation Factor VIII Historic Market Size by Country
5.1.1 North America Human Coagulation Factor VIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Human Coagulation Factor VIII Sales in Volume by Country (2018-2023)
5.1.3 North America Human Coagulation Factor VIII Sales in Value by Country (2018-2023)
5.2 North America Human Coagulation Factor VIII Forecasted Market Size by Country
5.2.1 North America Human Coagulation Factor VIII Sales in Volume by Country (2024-2029)
5.2.2 North America Human Coagulation Factor VIII Sales in Value by Country (2024-2029)
6 Europe Human Coagulation Factor VIII by Country
6.1 Europe Human Coagulation Factor VIII Historic Market Size by Country
6.1.1 Europe Human Coagulation Factor VIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Human Coagulation Factor VIII Sales in Volume by Country (2018-2023)
6.1.3 Europe Human Coagulation Factor VIII Sales in Value by Country (2018-2023)
6.2 Europe Human Coagulation Factor VIII Forecasted Market Size by Country
6.2.1 Europe Human Coagulation Factor VIII Sales in Volume by Country (2024-2029)
6.2.2 Europe Human Coagulation Factor VIII Sales in Value by Country (2024-2029)
7 Asia-Pacific Human Coagulation Factor VIII by Region
7.1 Asia-Pacific Human Coagulation Factor VIII Historic Market Size by Region
7.1.1 Asia-Pacific Human Coagulation Factor VIII Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Human Coagulation Factor VIII Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Human Coagulation Factor VIII Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Human Coagulation Factor VIII Forecasted Market Size by Region
7.2.1 Asia-Pacific Human Coagulation Factor VIII Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Human Coagulation Factor VIII Sales in Value by Region (2024-2029)
8 Latin America Human Coagulation Factor VIII by Country
8.1 Latin America Human Coagulation Factor VIII Historic Market Size by Country
8.1.1 Latin America Human Coagulation Factor VIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Human Coagulation Factor VIII Sales in Volume by Country (2018-2023)
8.1.3 Latin America Human Coagulation Factor VIII Sales in Value by Country (2018-2023)
8.2 Latin America Human Coagulation Factor VIII Forecasted Market Size by Country
8.2.1 Latin America Human Coagulation Factor VIII Sales in Volume by Country (2024-2029)
8.2.2 Latin America Human Coagulation Factor VIII Sales in Value by Country (2024-2029)
9 Middle East and Africa Human Coagulation Factor VIII by Country
9.1 Middle East and Africa Human Coagulation Factor VIII Historic Market Size by Country
9.1.1 Middle East and Africa Human Coagulation Factor VIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Human Coagulation Factor VIII Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Human Coagulation Factor VIII Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Human Coagulation Factor VIII Forecasted Market Size by Country
9.2.1 Middle East and Africa Human Coagulation Factor VIII Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Human Coagulation Factor VIII Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Shire (Baxter)
10.1.1 Shire (Baxter) Company Information
10.1.2 Shire (Baxter) Introduction and Business Overview
10.1.3 Shire (Baxter) Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Shire (Baxter) Human Coagulation Factor VIII Products Offered
10.1.5 Shire (Baxter) Recent Development
10.2 Bayer
10.2.1 Bayer Company Information
10.2.2 Bayer Introduction and Business Overview
10.2.3 Bayer Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Bayer Human Coagulation Factor VIII Products Offered
10.2.5 Bayer Recent Development
10.3 CSL
10.3.1 CSL Company Information
10.3.2 CSL Introduction and Business Overview
10.3.3 CSL Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.3.4 CSL Human Coagulation Factor VIII Products Offered
10.3.5 CSL Recent Development
10.4 Pfizer
10.4.1 Pfizer Company Information
10.4.2 Pfizer Introduction and Business Overview
10.4.3 Pfizer Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Pfizer Human Coagulation Factor VIII Products Offered
10.4.5 Pfizer Recent Development
10.5 Grifols
10.5.1 Grifols Company Information
10.5.2 Grifols Introduction and Business Overview
10.5.3 Grifols Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Grifols Human Coagulation Factor VIII Products Offered
10.5.5 Grifols Recent Development
10.6 Biogen
10.6.1 Biogen Company Information
10.6.2 Biogen Introduction and Business Overview
10.6.3 Biogen Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Biogen Human Coagulation Factor VIII Products Offered
10.6.5 Biogen Recent Development
10.7 Octapharma
10.7.1 Octapharma Company Information
10.7.2 Octapharma Introduction and Business Overview
10.7.3 Octapharma Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Octapharma Human Coagulation Factor VIII Products Offered
10.7.5 Octapharma Recent Development
10.8 NovoNordisk
10.8.1 NovoNordisk Company Information
10.8.2 NovoNordisk Introduction and Business Overview
10.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.8.4 NovoNordisk Human Coagulation Factor VIII Products Offered
10.8.5 NovoNordisk Recent Development
10.9 Greencross
10.9.1 Greencross Company Information
10.9.2 Greencross Introduction and Business Overview
10.9.3 Greencross Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Greencross Human Coagulation Factor VIII Products Offered
10.9.5 Greencross Recent Development
10.10 Kedrion
10.10.1 Kedrion Company Information
10.10.2 Kedrion Introduction and Business Overview
10.10.3 Kedrion Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Kedrion Human Coagulation Factor VIII Products Offered
10.10.5 Kedrion Recent Development
10.11 BPL
10.11.1 BPL Company Information
10.11.2 BPL Introduction and Business Overview
10.11.3 BPL Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.11.4 BPL Human Coagulation Factor VIII Products Offered
10.11.5 BPL Recent Development
10.12 Hualan Bio
10.12.1 Hualan Bio Company Information
10.12.2 Hualan Bio Introduction and Business Overview
10.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Hualan Bio Human Coagulation Factor VIII Products Offered
10.12.5 Hualan Bio Recent Development
10.13 RAAS
10.13.1 RAAS Company Information
10.13.2 RAAS Introduction and Business Overview
10.13.3 RAAS Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.13.4 RAAS Human Coagulation Factor VIII Products Offered
10.13.5 RAAS Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Human Coagulation Factor VIII Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Human Coagulation Factor VIII Industrial Chain Analysis
11.4 Human Coagulation Factor VIII Market Dynamics
11.4.1 Human Coagulation Factor VIII Industry Trends
11.4.2 Human Coagulation Factor VIII Market Drivers
11.4.3 Human Coagulation Factor VIII Market Challenges
11.4.4 Human Coagulation Factor VIII Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Human Coagulation Factor VIII Distributors
12.3 Human Coagulation Factor VIII Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
